The fact is as our balance sheet continues to strengthen, our flexibility here, strategic flexibility goes up, and we will look at acquiring technologies that make sense from a mission standpoint for the company, that we see a path to leadership in, that we think will increase our weighted average market growth because that’s important for sustainability, and we see a path to be able to increase growth rate and EPS. I’ve said before there are three areas that we’ll look at for acquisitions, mainly kind of smaller to midsized deals, but we’d look at things that would enhance our position in recon in those faster growth sub-markets – that could be robotics, data, or the ASC setting. In orthopedic area diversification, that would be in faster growth sub-segments like sports or CMFT or extremities, and then as you said, those things that might be outside of orthopedics that would help us diversify the business away from elective procedures but also in fast growth markets.
All of those things are on the table right now, and again as our balance sheet strengthens, our ability to action that obviously also increases. We’re going to stay disciplined, there’s no question about it, but we are clearly on the hunt for targets that make sense in those ways.
Travis Steed: Great, thanks for the color.
Keri Mattox: Thanks for the question, Travis. Katie, we can go to the next question in the queue.
Operator: We’ll go next to Drew Ranieri with Morgan Stanley.
Drew Ranieri: Hi, good morning Bryan and Suke. Thanks for taking the question. Maybe Bryan, just to start, a question for you. You’ve talked about your confidence in the business, and I understand that your thinking is this year’s not normal relative to pre-pandemic times, but it’s been a while since you last discussed long term plans. I’m just curious how you’re thinking about the business longer term and your confidence in gross margin expansion opportunities ahead. Just anything that you could help frame investors with in terms of thinking about the business from a margin or growth perspective.
Bryan Hanson: Yes, so maybe I’ll start, and Suke, I’ll pass it to you on the margin side. I would say our team’s confidence is as high as it’s ever been, quite frankly. Just think about that in the short term – it is not a normal environment. There are a lot of challenges that we’re having to deal with from a supply chain standpoint. But I do go back to what I said in the prepared remarks – I have a lot of confidence in this team because of the muscle memory we have over the last five years of dealing with a lot of adversity. So just in this moment of a non-normal environment, I would rather have this team than any other team because I believe they can fight through those challenges, and they’ve proven it. That’s number one.
Number two, outside of those challenges, we’re just hitting our stride. From a momentum standpoint, we’ve had a lot of kickoff meetings here recently – I love to go to those meetings. You get a real sense for how people are feeling, just having a conversation with sales reps, that’s where it all starts. The momentum there, the confidence there, the belief there is as good as I’ve ever seen it, so all those things add up to me to say, particularly in a normal environment, we’re in a good place and I feel confident that we can continue to deliver the innovation and drive real revenue growth. I don’t want to give too many views of what the future revenue growth of the company will be, but know this – as we increase the weighted average market growth of the company, as we get to a 4% that’s organic that we can commit to and sustain, that won’t be good enough.
